Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 985-990, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kerrigan, S.
Right arrow Articles by Brooks, Donald. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kerrigan, S.
Right arrow Articles by Brooks, Donald. E.
Related Collections
Right arrow Drug Monitoring and Toxicology
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 1998;44:985-990.)
© 1998 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

Indirect enzyme-linked immunosorbent assay for the quantitative estimation of lysergic acid diethylamide in urine

Sarah Kerrigan1, and Donald. E. Brooks1,2,a

Departments of
1 Chemistry and
2 Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, V6T 2B5 Canada.
a Address correspondence to this author at: Department of Pathology and Laboratory Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, B.C., V6T 2B5 Canada. Fax 604-822-7635;

A new antibody to lysergic acid diethylamide (LSD) was used to develop a novel indirect ELISA for the quantification of drug in urine. Evaluation of the new assay with the commercially available LSD ELISA (STC Diagnostics) shows improved performance. The test requires 50 µL of urine, which is used to measure concentrations of drug in the µg/L to ng/L range. The limit of detection was 8 ng/L compared with 85 ng/L in the commercial assay, and analytical recoveries were 98–106%. Our test detected 0.1 µg/L of LSD in urine with an intraassay CV of 2.4% (n = 8) compared with 6.0% for a 0.5 µg/L sample in the commercial assay (n = 20). The upper and lower limits of quantification were estimated to be 7 µg/L and 50 ng/L, respectively. Specificity was evaluated by measuring the extent of cross-reactivity with 24 related substances. Drug determination using the new assay offers both improved sensitivity and precision compared with existing methods, thus facilitating the preliminary quantitative estimation of LSD in urine at lower concentrations with a greater degree of certainty.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
G. Skopp, L. Potsch, R. Mattern, and R. Aderjan
Short-Term Stability of Lysergic Acid Diethylamide (LSD), N-Desmethyl-LSD, and 2-Oxo-3-hydroxy-LSD in Urine, Assessed by Liquid Chromatography-Tandem Mass Spectrometry
Clin. Chem., September 1, 2002; 48(9): 1615 - 1618.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.